

Drug Monograph

Drug/Drug **Armonair® Respiclick™ (fluticasone propionate) powder**
 Class: **for inhalation/ Inhaled Corticosteroids**
 Prepared for: MO HealthNet
 Prepared by: Conduent-Heritage

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Armonair® Respiclick™ is a multidose, inhalation-driven, dry powder for oral inhalation that meters 55 mcg, 113 mcg, or 232 mcg of fluticasone propionate from the device reservoir.

Manufacturer: Teva Respiratory, LLC, Frazer, PA 19355

Indications: Armonair® Respiclick™ is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older.

Costs: \$156.74 per 55 mcg inhaler and \$209.87 per inhaler for 113 mcg and 232 mcg Armonair® Respiclick™. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL

Type of PA Criteria: Increased Risk of ADE Under Solicitation
 Appropriate Indications Non Preferred

Prepared By: Luke Boehmer Pharm.D.
 Date: November 7, 2017